Ca§aSEID!Or<fii.I:BI87MI'Nl91®KlDdDom.aneBti-IB Filed 0>M(;l9/1@ Page 1 of 1 PageiD #: 3363
`
`~ AO 120 (Rev. 3/041
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S. C.§ 290 and/or 15 U.S. C.§ 1116 you are hereby advised that a court action has been
`G Trademarks:
`Southern District of Indiana on the following ~atents or
`filed in the U.S. District Court
`
`Dq~lv~f!376-TWP-DM DATE Fir&J29!201 0
`PLAINTIFF
`
`Ell LILLY AND COMPANY
`
`U.S. DISTRICT COURT Southern District of Indiana
`
`DEFENDANT
`
`TEVA PARENTERAL MEDICINES, INC., APP
`PHARMACEUTICALS, LLC, PLIVA HRVATSKA D.O.O.,
`TEVA PHARMACEUTICALS USA INC., and BARR LAB
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`PATENTOR
`TRADEMARK NO.
`
`1 7,772, 209 82
`
`INCLUDED BY
`
`G Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`G Answer
`G Cross Bill
`HOLDER OF PATENT OR TRADEMARK
`
`(b Other Pleading
`
`8/10/2010
`
`CLET NIYIKIZA, Inventor
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`Closed Judgment dated 3/31/2014, see attached.
`
`Copy 1-Upon initiation of action, mail this copy to Direc~opy 3-Upon termination of action, mail this copy to Director
`Copy 2-Upon filing document adding patent(s). mail this copy to Director Copy 4-Case file copy
`
`NEPTUNE GENERICS 1002- 00001
`APOTEX 1002 - 0001
`
`

`
`Case 1:14-cv-00104-TWP-DKL Document 28 Filed 01/23/14 Page 1 of 1 PageiD #: 96
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`for the Southern District of Indiana
`filed in the U.S. District Court
`on the following
`D Trademarks or
`( D the patent action involves 35 U.S.C. § 292.):
`[if Patents.
`
`DOCKET NO.
`1 :14-104-TWP-DKL
`PLAINTIFF
`
`DATE FILED
`1/23/2014
`
`U.S. DISTRICT COURT
`for the Southern District of Indiana
`DEFENDANT
`
`Ell LILLY AND COMPANY
`
`GLENMARK GENERICS INC., USA
`GLEN MARK PHARMACEUTICALS L TO
`GLEN MARK GENERICS L TO.
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`I 7,7772.209
`
`8/10/2010
`
`Ell LILLY AND COMPANY
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`D Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`0 Answer
`
`0 Cross Bill
`
`D Other Pleading
`
`IIOLDEROFPATENTOR TRADEMARK
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`CLERK ~ (BY) DEPUTY CLERK ~~ ~~n~~wv
`
`DATE
`
`1/23/2014
`
`to Director Co 3--r on terminohi on of action mail this co
`Co 1-U on initiation of action, mail this co
`PY to Director
`PY
`P
`,
`PY
`P
`PY
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4--Case file copy
`
`II
`\
`
`NEPTUNE GENERICS 1002-00002
`APOTEX 1 002 - 0002
`
`

`
`Case 1:13-cv-01469-TWP-DML Document 7 Filed 09/17/13 Page 1 of 1 PageiD # 27
`
`. AU Ull (Hn :l/01)
`
`·ro:
`
`Mail StopS
`Director oftht> U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S. C. !:j 290 and/or 15 U.S.C !:j 1116 you ;u·e her('by advised that a court action has been
`G Trademarks:
`~atents or
`Southern Dtstrict of lndianaonthP following
`l'iiPd in tlw US District Court
`
`D~Cr~:;r~':J?469-TWP-DM DATE Fllg)~312013
`PLAINTIFF
`
`ELl LILLY AND COMPANY
`
`U.S. DISTRICT COURT Southern District of Indiana
`
`DEFENDANT
`
`SUN PHARMACEUTICAL INDUSTRIES LTD.: SUN
`PHARMA GLOBAL FZE
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`I 7,772.209
`
`8/10/2010
`
`Ell LILLY AND COMPANY
`
`2
`
`3
`
`.j
`
`5
`
`In the above--entitled case. the follov.ing patent{s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`G Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`G Other Pleading
`G Cross Bill
`G Answer
`HOLDE!< OF PATENT OR TI<ADEMAI<K
`
`I
`
`2
`
`3
`
`1
`
`5
`
`I \lECISIONIJU UG EM£"
`
`In the above-entitled case. the following decision has OI'Pn rendered or judgement issued:
`
`CLEI~K
`
`DATE
`
`9/17/2013
`
`-Upon termination or action, mail this copy to Director
`Copy !-Upon initiation of action, mail this copy to Director
`Copy 2--lJpon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`NEPTUNE GENERICS 1002- 00003
`APOTEX 1 002 - 0003
`
`

`
`Trials@uspto.gov
`571-272-7822
`
`PaperNo. 13
`Date Entered: October 1, 2013
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`ACCORD HEAL THCARE, INC., USA
`Petitioner
`
`v.
`
`ELI LILLY & COMPANY
`Patent Owner
`
`Case IPR20 13-00356
`Patent 7,772,209
`
`Before MICHAEL J. FITZPATRICK, RAMA G. ELLURU, and
`SCOTI E. KAMHOLZ, Administrative Patent Judges.
`
`KAMHOLZ, Administrative Patent Judge.
`
`DECISION
`Denying Inter Partes Review
`37 C.F.R. § 42.108
`
`NEPTUNE GENERICS 1002- 00004
`APOTEX 1 002 - 0004
`
`

`
`IPR2013-00356
`Patent 7,772,209
`
`I.
`
`INTRODUCTION
`
`Accord Healthcare, Inc., USA, ("Accord") filed a petition (Paper 4) on
`
`June ~4, 2013 to institute an inter partes review of claims 1-22 ofU.S.
`
`Patent 7,772,209 ("the '209 patent"). Accord later filed a corrected petition (Paper
`
`6, "Pet."). Patent Owner Eli Lilly & Company ("Eli Lilly") filed a preliminary
`
`response (Paper 10, "Prelim. Resp."). The Board, acting on behalf of the Director,
`
`has jurisdiction under 35 U.S.C. § 314.
`
`The '209 patent is involved in several civil actions for patent infringement,
`
`including Eli Lilly & Co. v. Accord Healthcare, Inc., USA et al., 1: 12-cv-00086-
`
`TWP-DKL (S.D. Ind.) ("the '086 action"), filed January 20, 2012 and served
`
`January 23, 2012, and Eli Lilly & Co. v. Accord Healthcare, Inc., USA, 1 :13-cv-
`
`00335-TWP-DKL (S.D. Ind.) ("the '335 action"), filed February 28,2013 and
`
`served March 7, 2013. Pet. 1; Prelim. Resp. 5-6." The '335 action has been
`
`consolidated into the '086 action. Prelim. Resp. 6-7.
`
`We deny the petition because it is time-barred under 35 U.S.C. § 315(b).
`
`II.
`
`ANALYSIS
`
`Eli LilJy served Accord with a complaint aJleging infringement ofthe '209
`
`patent on at least two occasions: the '086 action, on January 23,2012, and the
`
`'355 action, on March 7, 2013. Ex. 2004 (return of service for the '086 action);
`
`Prelim. Resp. 5-6; see also Pet. 1. The earlier complaint was served more than one
`
`year before Accord filed the present petition; the latter, less than one year.
`
`, • The parties disagree as to whether the complaint in the '355 action ~as served on
`February 28, 2013 or March 7, 2013. For purposes of this decision, we accept Eli
`Lilly's representation that the complaint was served on March 7, 2013.
`2
`
`NEPTUNE GENERICS 1002- 00005
`APOTEX 1 002 - 0005
`
`

`
`IPR20 13-003 56
`Patent 7, 772,209
`
`Section 315(b) ofTitle 35 ofthe United States Code provides:
`
`(b) PATENT OWNER'S ACTION.-An inter partes
`review may not be instituted if the petition requesting the
`proceeding is filed more than 1 year after the date on
`which the petitioner, real party in interest, or privy of the
`petitioner is served with a complaint alleging infringe(cid:173)
`ment of the patent. The time limitation set forth in the
`preceding sentence shall not apply to a request for joinder
`under subsection (c).
`
`Accord argues that its petition is timely because it was filed less than one
`
`year after the date on which it was served with a complaint in the '355 action.
`
`Pet. 2-3. Accord acknowledges service on January 23, 2012 of a complaint in the
`
`'086 action, but argues that the two infringement actions concern distinct products
`
`and are based on different sets of facts. !d. at 3 n.l.
`
`We reject Accord's implicit argument that the one-year period set forth in
`
`§ 315(b) should not be measured from the date of service ofthe complaint in the
`
`'086 action. The plain language of the statute does not indicate or suggest that the
`
`filing of a later lawsuit renders the service of a complaint in an earlier lawsuit a
`
`nullity. Moreover, as the legislative history of35 U.S.C. § 315(b) indicates,
`
`Congress intended that inter partes reviews should not be used as "tools for
`
`harassment" by "repeated litigation and administrative attacks." H.R.Rep. No.
`
`112-98 at 48 (2011). Allowing such attacks "would frustrate the purpose ofthe
`
`section as providing quick and cost effective alternatives to litigation." /d.
`
`Accord was "served with a complaint alleging infringement ofthe patent'1 on
`
`January 23, 2012. Ex. 2004. The petition was filed more than one year after that
`
`date and is, therefore, barred. See Universal Remote Control, Inc. v. Universal
`
`Elec., Inc., IPR2013-00168, Paper 9 at 4 (PTAB Aug. 26, 2013).
`
`3
`
`NEPTUNE GENERICS 1002- 00006
`APOTEX 1 002 - 0006
`
`

`
`IPR2013-00356
`Patent 7,772,209
`
`III. CONCLUSION .
`
`The Board denies the petition because it was not filed within the time limit
`
`imposed by 35 U.S.C. § 315(b).
`
`IV. ORDER
`
`For the reasons given, it is
`
`ORDERED that the petition challenging the patentability of claims 1-22 of
`
`U.S. Patent 7, 772,209 is denied.
`
`4
`
`NEPTUNE GENERICS 1002- 00007
`APOTEX 1 002 - 0007
`
`

`
`IPR2013-00356
`Patent 7, 772,209
`
`For Petitioner:
`
`Chidambaram S. Iyer
`Chandran B. lyer
`Sughrue Mion PLLC
`
`For Patent Owner:
`
`Andrew V. Trask
`Williams & Connolly LLP
`
`Mark J. Stewart
`Eli Lilly & Company
`
`5
`
`NEPTUNE GENERICS 1002- 00008
`APOTEX 1 002 - 0008
`
`

`
`Case 1:13-cv-00335-TWP-DKL Document 29 Filed 07/01113 Page 1 of 1 PageiD #: 129
`
`<l::. AO 120 {Rev. 3/04)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S. C.§ 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`~Patents or
`G Trademarks·
`Southern District of Indiana on the following
`..
`filed in the US District Court
`
`nqW-lv~5-TWP-DKL DATE FI~812013
`PLAINTIFF
`
`U.S. DISTRICT COURT Southern District of Indiana
`
`DEFENDANT
`
`Ell LILLY AND COMPANY
`
`ACCORD HEAL THCARE INC., USA
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`1 7,772,209
`
`HOLDER OF PATENT OR TRADEMARK
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATEI~h~J2Wh
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`G Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`G Answer
`
`G Cross Bill
`
`G Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`ORDER OF CONSOLIDATION -This cause of action is hereby consolidated under action 1 :12-cv-86-TWP-DKL.
`
`CLERK%~~
`
`DATE
`
`7/1/2013
`
`C py 3-Upon termination of action, mail this copy to Director
`Copy 1-Upon initiation of action, mail this copy to Direc
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`NEPTUNE GENERICS 1002- 00009
`APOTEX 1 002 - 0009
`
`

`
`Case 1:13-cv-00335-TWP-DKL Document 9 Filed 03111113 Page 1 of 1 PageiD #: 28
`
`~ AO 120 (Rev. 3104)
`
`TO:
`
`Mail Stop 8
`Director ofthe U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`G Trademarks·
`Southern District of Indiana on the following @(Patents or
`..
`filed in the US District Court
`nq~Jv!~t~b335-TWP-D~ DATE FlYf2lBt20 13
`PLAINTIFF
`
`U.S. DISTRICT COURT Southern District of Indiana
`
`DEFENDANT
`
`ELl LILLY AND COMPANY
`
`ACCORD HEAL THCARE INC., USA
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`1 7,772,209
`
`HOLDER OF PATENT OR TRADEMARK
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case. the following patent(s)l trademark(s) have been included:
`
`DATE INCLUDED
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`G Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`G Answer
`
`G Cross Bill
`
`G Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case. the following decision has been rendered or judgement issued:
`
`IDECJS!ON/jUDGEMENT
`
`Upon termination of action, mail this copy to Director
`Copy 1-Upon initiation of action, mail this mpy to Director Copy
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`DATE
`
`3/11/2013
`
`NEPTUNE GENERICS 1002- 00010
`APOTEX 1002 - 0010
`
`

`
`Case 1:10-cv-01376-TWP-DKL Document 154 Filed 10/02/12 Page 1 of 1 PageiD #: 2592
`
`~ AO 120 (Rev. 3/04)_
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S. C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`G Trademarks:
`Southern District of Indiana on the following
`filed in the U.S. District Court
`Q('Patents or
`DATE FlrlfJ29!20 1 0
`
`U.S. DISTRICT COURT Southern District of Indiana
`
`DEFENDANT
`
`TEVA PARENTERAL MEDICINES, INC., APP
`PHARMACEUTICALS, LLC, PLIVA HRVATSKA 0.0.0.,
`TEVA PHARMACEUTICALS USA INC, and BARR LAB
`
`HOLDER OF PATENT OR TRADEMARK
`
`DOC~~U~~~ 1376-P/L
`PLAINTIFF
`
`Ell LILLY AND COMPANY
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`1 7,772,209
`
`8/10/2010
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`INCLUDED BY
`
`~Amendment G Answer
`DATE OF PATENT
`HOLDER OF PATENT OR TRADEMARK
`OR TRADEMARK
`
`G Cross Bill
`
`G Other Pleading
`
`**SEE ATTACHED AMENDED COMPLAINT**
`
`DATE I~hW21R 2
`
`PATENTOR
`TRADEMARK NO.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`IDECISION/]UDGEMENT
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3-Upon termination of action, mail this copy to Director
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`DATE
`
`10/2/2012
`
`NEPTUNE GENERICS 1002-00011
`APOTEX 1002 - 0011
`
`

`
`Case 1 :11-cv-00942-TWP-TAB Document 12 Filed 09/12/11 Page 1 of 1 PageiD #: 54
`
`'Q. AO 120 (Rev 3/04)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S. C.§ 1116 you are hereby advised that a court action has been
`Southern District of Indiana on the following G Patents or
`G Trademarks:
`filed in the U.S. District Court
`
`Dqq'i~Jv~42-TWP-TAB DATE FI17~5/2011
`PlAINTIFF
`
`U.S. DISTRICT COURT Southern District of Indiana
`
`DEFENDANT
`
`Ell LILLY AND COMPANY
`
`APP PHARMACEUTICALS, LLC
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`1 7,772,209
`
`8/10/2010
`
`HOLDER OF PATENT OR TRADEMARK
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following patent (s)/ trademark(s) have been included:
`DATE INCLUDED
`INCLUDED BY
`
`G Answer
`
`G Cross Bill
`HOLDER OF PATENT OR TRADEMARK
`
`G Other Pleading
`
`G Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`PATENT OR
`TRADEMARK NO.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`DECISION/JUDGEMENT
`
`See attached Order of Consolidation.
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3-Upon termination of action, mail this copy to Director
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`DATE
`
`9112/2011
`
`NEPTUNE GENERICS 1002- 00012
`APOTEX 1002 - 0012
`
`

`
`Case 1:1 0-cv-01376-TWP-DKL Document 78 Filed 09/26/11 Page 1 of 1 PageiD #: 447
`
`'4 AO 120 (Rev 3/04)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S. C. § 290 and/or 15 U.S. C. § 1116 you are hereby advised th~ court action has been
`G Trademarks:
`filed in the U.S. District Court
`Southern District of Indiana on the following
`Vi"Patents or
`
`oq~.fif-lv~-?.376-TWP-DM DATE FIH)J29/201 0
`
`U.S. DISTRICT COURT Southern District of Indiana
`
`PLAINTIFF
`
`Ell LILLY AND COMPANY
`
`DEFENDANT
`
`TEVA PARENTERAL MEDICINES, INC., APP
`PHARMACEUTICALS, LLC, PLIVA HRVATSKA D.O.O.,
`TEVA PHARMACEUTICALS USA INC., and BARR LAB
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 7,772,209 B2
`
`8/10/2010
`
`CLET NIYIKIZA, Inventor
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`G Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`~Answer
`HOLDER OF PATENT OR TRADEMARK
`
`G Cross Bill
`
`Other Pleading
`
`I
`
`2
`
`3
`
`4
`
`5
`
`**See attached Answer to Complaint filed in
`
`Consolidated Case 1 :11-cv-942-TWP-TAB.**
`
`In the above-entitled case. the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`opy 3-Upon termination of action, mail this copy to Director
`Copy 1-Upon initiation of action, mail this copy to Direc
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`DATE
`9/26/2011
`
`NEPTUNE GENERICS 1002- 00013
`APOTEX 1002 - 0013
`
`

`
`Case 1 :11-cv-00942-TWP-TAB Document 8 F~ed 07/25/11 Page 1 of 1 PageiD #: 24
`
`~ AO 120 (Rev. 3/04)
`
`TO:
`
`Mail StopS
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S. C. § 290 and/or 15 U.S. C. § 1116 you are hereby advised that a court action has been
`Southern District of Indiana on the following G Patents or
`G Trademarks:
`filed in the U.S. District Court
`
`nq~~U~9l42-TWP-TAB DATE FILf1~5/2011
`PLAINTIFF
`
`U.S. DISTRICT COURT Southern District of Indiana
`
`DEFENDANT
`
`Ell LILLY AND COMPANY
`
`APP PHARMACEUTICALS, LLC
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 7,772,209
`
`8/10/2010
`
`**SEE ATTACHED COMPLAINT**
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`G Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`G Answer
`
`G Cross Bill
`
`G Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`ICLERK ~ I(BY)DE~~ IDATE 7/2512011
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3-Upon termination of action, mail this copy to Director
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`NEPTUNE GENERICS 1002- 00014
`APOTEX 1002 - 0014
`
`

`
`Case 1:1 0-cv-01376-TWP-DML Document 52 Filed 02/28/11 Page 1 of 1
`
`~ AO 120 (Rev. 3/04)
`
`TO:
`
`Mail Stop 8
`Director ofthe U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S. C.§ 290 and/or 1.5 ~.S.C.§ 11!6 you are hereby advised th~ court action has been
`G Trademarks:
`filed in the U.S. District Court
`Southern Dlstnct of Indiana on the following YPatents or
`
`0<f~Jv~f376-TWP-DM DATE FlrcrB9t201 0
`PLAINTIFF
`
`ELl LILLY AND COMPANY
`
`U.S. DISTRICT COURT Southern District of Indiana
`
`DEFENDANT
`
`TEVA PARENTERAL MEDICINES, INC., APP
`PHARMACEUTICALS, LLC, PLIVA HRVATSKA D.O.O.,
`TEVA PHARMACEUTICALS USA INC., and BARR LAB
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 7,772,209 82
`
`8/10/2010
`
`CLET NIYIKIZA, Inventor
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case. the following patent(s)/lrademark(s) have been included:
`DATE INCLUDED
`INCLUDED BY
`
`G Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`PATENT OR
`TRADEMARK NO.
`
`I
`
`2
`
`3
`
`4
`
`5
`
`~Answer
`HOLDER OF PATENT OR TRADEMARK
`**SEE ATIACHED ANSWER FILED ON 2/22/2011**
`
`G Cross Bill
`
`Other Pleading
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`DECISION/JUDGEMENT
`
`opy 3-Upon termination of action, mail this copy to Director
`Copy 1-Upon initiation of action, mail this copy to Direc
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4--Case file copy
`
`DATE
`2/28/2011
`
`NEPTUNE GENERICS 1002- 00015
`APOTEX 1002 - 0015
`
`

`
`Case 1:1 0-cv-01376-TWP-DML Document 44 Filed 02/14/11 Page 1 of 1
`
`'<il. AO 120 (Rev. 3104)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 1.5 ~.S.C.§ 11.16 you are hereby advised th'!Jaj! court action has been
`G Trademarks·
`..
`~Palents or
`filed in the US District Court
`Southern Dlstnct of Indiana on the following
`
`D9~lv~?.376-TWP-DM DATE FltOB:9!20 1 0
`PLAINTIFF
`Ell LILLY AND COMPANY
`
`U.S. DISTRICT COURT Southern District of Indiana
`
`DEFENDANT
`
`TEVA PARENTERAL MEDICINES, INC., APP
`PHARMACEUTICALS, LLC, PLIVA HRVATSKA D.O.O.,
`TEVA PHARMACEUTICALS USA INC., and BARR LAB
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`I 7,772,209 B2
`
`8/10/2010
`
`CLET NIYIKIZA, Inventor
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been Included:
`DATE INCLUDED
`INCLUDED BY
`
`G Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`~Answer
`G Cross Bill
`HOLDER OF PATENT OR TRADEMARK
`***SEE ATTACHED ANSWER FILED ON 2/7/11***
`
`Other Pleading
`
`PATENTOR
`TRADEMARK NO.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`DECISION/JUDGEMENT
`
`CLERK~~
`
`DATE
`2/14/2011
`
`opy 3-Upon termination of action, mail this copy to Director
`Copy 1-Upon initiation of action, mail this copy to Direc
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`NEPTUNE GENERICS 1002- 00016
`APOTEX 1002 - 0016
`
`

`
`Case 1:10-cv-01376-TWP-DML DocumentS Filed 11/02/10 Page 1 of!
`"'l>. AD 120 (Rev 3/04)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S. C.§ 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`Southern District of Indiana on the following G Patents or
`G Trademarks:
`filed in the U.S. District Court
`
`Dq9ff-Jvt:JTh76-TWP-DM DATE FlfrOJ29t201 0
`
`Us. DISTRICT COURT Southern District of Indiana
`
`PLAINTIFF
`
`Ell LILLY AND COMPANY
`
`DEFENDANT
`
`TEVA PARENTERAL MEDICINES, INC., APP
`PHARMACEUTICALS, LLC, PLIVA HRVATSKA D.O.O.,
`TEVA PHARMACEUTICALS USA INC., and BARR LAB
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`I 7,772,209 82
`
`8/10/2010
`
`CLET NIYIKIZA, Inventor
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following patent(s]/ trademark(s) have been included:
`INCLUDED BY
`
`DATE INCLUDED
`
`PATENTOR
`TRADEMARK NO.
`
`G Amendment
`DATE OF PATENT
`DR TRADEMARK
`
`G Amwer
`
`G Cross Bill
`
`~ Other Pleading
`
`HOLDER OF PATENT DR TRADEMARK
`
`1 7,772, 209 82
`
`8/10/2010
`
`***SEE ATTACHED COMPLAINT FILED ON 10/29/2010***
`
`2
`
`3
`
`4
`
`5
`
`In the above-enlitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`CLERK 5~
`
`DATE
`
`11/2/2010
`
`opy 3-Upon termination of action, mail this copy to Director
`Copy 1-Upon initiation of action, mail this copy to Direc
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`NEPTUNE GENERICS 1002-00017
`APOTEX 1002 - 0017
`
`

`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`CERTIFICATE OF CORRECTION
`
`: 7,772,209 B2
`PATENT NO.
`APPLICATIONNO. : 11/776329
`DATED
`:August 10, 2010
`: Clet Niyikiza
`INVENTOR(S)
`
`Page 1 of 1
`
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:
`
`Title Page, Col. 2, Line 22, under Other Publications: Delete
`"Homocystein" and insert --Homocysteine--, therefor.
`
`Title Page, Col. 2, Line 27, under other Publications: Delete
`"hydroxocobaltniin" and insert --hydroxocobalamin--, therefor.
`
`Title Page, Col. 2, Line 28, under Other Publications: Delete
`"mce" and insert --mice--, therefor.
`
`Title Page, Col. 2, Line 37, under Other Publications: Delete
`"2666" and insert --266--, therefor.
`
`Column 1, Line 5, Delete "12 May," and insert --5 Dec.--, therefor.
`
`Column 10, Line 62, In Claim 1, delete "hydroxycobalamin,"
`and insert --hydroxocobalamin,--, therefor.
`
`Column 11, Line 4, In Claim 4, delete "2," and insert --3,--, therefor.
`
`Signed and Sealed this
`
`Twenty-sixth Day of October, 2010
`
`David J. Kappas
`Director of the United States Patent and Trademark Olfice
`
`NEPTUNE GENERICS 1002-00018
`APOTEX 1002 - 0018
`
`

`
`PATENT
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`U. S. Patent No.
`
`Issued:
`
`First Applicant
`
`Serial No.
`
`Application Date
`
`Entitled
`
`Docket No.
`
`7,772,209
`
`August 10, 2010
`
`Clet Niyikiza
`
`11/776,329
`
`July 11, 2007
`
`Antifolate Combination Therapies
`
`Xl4173B
`
`REQUEST FOR CERTIFICATE OF CORRECTION
`UNDER 37 C.F.R. 1.322
`
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Sir:
`
`The patentee of the above-identified patent respectfully requests that you issue
`
`a Certificate of Correction to correct errors in the printed patent. Attached is Form PTO 1050
`
`on which the errors are specified.
`
`Some of the errors are typographical and were made inadvertently. The
`
`remaining errors occurred during the printing of the patent.
`
`Please charge the fee under 1.20(a) and charge any additional fees which may
`
`be required by this or any other related paper, or credit any overpayment to Deposit Account
`
`No. 05-0840 to cover the cost of this Certificate of Correction.
`
`Respectfully submitted,
`
`/Elizabeth A. McGraw/
`Elizabeth A. McGraw
`Attorney for Applicant
`Registration No. 44,646
`Phone: 317-277-7443
`
`Eli Lilly and Company
`Patent Division
`P.O. Box 6288
`Indianapolis, Indiana 46206-6288
`September 20, 2010
`
`NEPTUNE GENERICS 1002- 00019
`APOTEX 1002 - 0019
`
`

`
`PTOiS6i44 (0\J-07:•
`r~;:-prl')v~~ tOt ~e: thro~gh oaJ~~/ZOltt or ... ~s 0651·0033
`U.S. Pa!Bnt 8nd Tmdema>i< Offi,_,.; U.S. DEPARTMENT OF COMMERCE
`UnrJ1:.•~ th~ Papmv·.-'Ofk RedtJ·c~jnn Act of 1995, ao tH;·E:iJt~~ m~,~ t\?.qt:ked to rt·spond ~o a t-oi!Gc~ft.ll~\ ~'jf lilft~tm;;.ltl(tn lm~t~~~ tt d;t;~~~t;;ys a vaik:l OMS C<:mtrol nlfmber.
`~'Also FonYt PT0-1 0501
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO_
`
`7,772,209
`
`Page _1_ of _1_
`
`APPLICATION NO. 11/776,329
`August 10, 2010
`Clet Niyikiza
`
`INVENTOR(S)
`
`ISSUE DATE
`
`It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent
`is hereby corrected as shown below:
`
`First l?~ige, Col. 2, Line 22, u.w .. '!.er- Other Publications: Delete
`"Homocyst.ein" and i.nserr .. --Homocystei.ne--, therefor.
`
`First Page, Col. 2, Line 27, under Other Publications: Delete
`"hydroxocoba.1.tniin" and insert ~-hydroxocobalamin~-, therefor.
`
`First Page, Col. 2, Line 28, under Other Publications: Delete
`"mce" and inse:t-t -- --mice-- --,
`thco:cef or·.
`
`First Page, Col. 2, Line 37, under Other Publications: Delete
`"2666" and inse:ct ----266----, therefor.
`
`Column 1, LineS: Delete "12 J'vl,:ly," and insert.--=, Dec.--, therefor.
`
`Column 10, L,ine 6~': In Claim 1, delete "hydroxycobal."J_min,"
`c.md insert ~-hydroxocobalamin, - ~, therefor.
`
`Column 11, Line ·~: In Claim 4~ delete "2," and insert
`
`therefor·.
`
`MAILING ADDRESS OF SENDER (Please do not use customer number below):
`Eli Lilly and Company
`P.O. Box 6288
`Indianapolis, IN 46206-6288
`This r::n!;r.;-r;~inn nf infonnatiiJn i:;;; •~quln~d hy 3.7 CFR t 322, I 37.3. ;;md i .324. Thcr ktim1n.:-1tlon is r~q~JlrP.d to nhto.-~tn nr ~<:l't;~;n, ~~ b~n~ft~ hy it~:P.> pub~ir.. ~ovhich ;~ to f11B
`(and t>y lhG USPTO t(> ~·tCC<3SS) an ~PI'Iicaiicrl Cor.IJd<:mtb!it}' is govoi>med by 35 V.S.C. ·122 ;O>I1d ·n CFR L14. l"tli;; co!l~c\icn is ostirnat(>d to \~kG 1.0 hew t(;
`C"!";.rnr.M:te, ~nclud~ng: gH~hi';;fing, preparjng, and submHt~ng th.e cornp~~~::ted appHt.:.f"3tinn fmrn to the USPTO. Tkfl<:~ wm Vi3ry d~:-:>pending BpGn ih:e ~fH.iiv~du;3t c.aso;-::. An:t
`:r..:ornn1~.mts. tJtl the <)ffH)tJrlt ··.~f tltne yo·u ~1~w:~r~ 10· co:npiete this torFn 3r:d~o.r $1lgges!ions f<X r-edudr-l~ thi~;; bl:rden, ~fi'l)t~ld b.:s s.:snt k) ~t-1~ Ct-1ief ~n~.:~~n1;.::;t~o~1 Oii'i..:..~;-.
`U.S. P~to;;.nt and Tr~cl~m~fi..: Oftke. U.S. D~::~partment ot Commerce, P,O Box i450, .A.!e:<:andd~. \/A 223t3£14SO. DO NOT SEND fEES OR COMPLETED
`FORMS TO THIS ADDRESS. SENO TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria,
`VA 22313-1450.
`
`If you need assislanc<> in completing tire form, call 1--801J~PT0.9199 and select option 2.
`
`NEPTUNE GENERICS 1002-00020
`APOTEX 1 002 - 0020
`
`

`
`Electronic Patent Application Fee Transmittal
`
`Application Number:
`
`Filing Date:
`
`11776329
`
`11-Jul-2007
`
`Title of Invention:
`
`NOVEL ANTI FOLATE COMBINATION THERAPIES
`
`First Named Inventor/Applicant Name:
`
`Clet Niyikiza
`
`Filer:
`
`Elizabeth Ann McGraw/Linda Durbin
`
`Attorney Docket Number:
`
`X14173B
`
`Filed as Large Entity
`
`Utility under 35 USC 111 (a) Filing Fees
`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USD($)
`
`Basic Filing:
`
`Pages:
`
`Claims:
`
`Miscellaneous-Filing:
`
`Petition:
`
`Patent-Appeals-and-Interference:
`
`Post-Allowance-and-Post-Issuance:
`
`Certificate of correction
`
`1811
`
`1
`
`100
`
`100
`
`Extension-of-Time:
`
`NEPTUNE GENERICS 1002- 00021
`APOTEX 1002 - 0021
`
`

`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USD($)
`
`Miscellaneous:
`
`Total in USD ($)
`
`100
`
`NEPTUNE GENERICS 1002-00022
`APOTEX 1 002 - 0022
`
`

`
`Electronic Acknowledgement Receipt
`
`EFSID:
`
`Application Number:
`
`8464324
`
`11776329
`
`International Application Number:
`
`Confirmation Number:
`
`6568
`
`Title of Invention:
`
`NOVEL ANTI FOLATE COMBINATION THERAPIES
`
`First Named Inventor/Applicant Name:
`
`Clet Niyikiza
`
`Customer Number:
`
`25885
`
`Filer:
`
`Elizabeth Ann McGraw/Linda Durbin
`
`Filer Authorized By:
`
`Elizabeth Ann McGraw
`
`Attorney Docket Number:
`
`X14173B
`
`Receipt Date:
`
`Filing Date:
`
`TimeStamp:
`
`21-SEP-201 0
`
`11-JUL-2007
`
`15:28:58
`
`Application Type:
`
`Utility under 35 USC 111 (a)
`
`Payment information:
`
`Submitted with Payment
`
`Payment Type
`
`Payment was successfully received in RAM
`
`RAM confirmation Number
`
`Deposit Account
`
`Authorized User
`
`yes
`
`Deposit Account
`
`$100
`
`1875
`
`050840
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)
`
`NEPTUNE GENERICS 1002- 00023
`APOTEX 1 002 - 0023
`
`

`
`File Listing:
`
`Document
`Number
`
`Document Description
`
`FileName
`
`File Size( Bytes)/
`Message Digest
`
`Pages
`Multi
`Part/.zip (ifappl.)
`
`1
`
`Request for Certificate of Correction
`
`X14173BReq uestCertificateofC
`orrection.pdf
`
`276775
`
`3 dfd 3cab096 751J 3cd0618f3 e2 c3 2e60ff56 7
`lbdO
`
`no
`
`2
`
`Warnings:
`
`Information:
`
`2
`
`Fee Worksheet (PT0-875)
`
`fee-info.pdf
`
`no
`
`2
`
`30372
`
`23f9dc93ad89b23edb112ce21d94211041f
`77'J77
`
`Warnings:
`
`Information:
`
`Total Files Size (in bytes)
`
`307147
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evi